United States Patent 9,872,906: Ceftolozane-Tazobactam Composition Claims, Patent Scope, and Competitive Landscape

U.S. Patent No. 9,872,906 protects quality attributes of ceftolozane-tazobactam solid compositions, rather than the antibiotic combination itself. Its claims require a 2:1 active-ingredient ratio and impose measured impurity limits after defined storage periods at 25°C and 60% relative humidity. The patent is most relevant to lyophilized or otherwise solid injectable products containing ceftolozane sulfate and tazobactam sodium, including the 1,000 mg/500 mg and 2,000 mg/1,000 mg dose presentations used for Zerbaxa.

The patent creates an analytical and formulation barrier. A competing product would not necessarily infringe merely because it contains ceftolozane and tazobactam at a 2:1 ratio. Infringement depends on whether the product satisfies the specified impurity thresholds under the claimed storage protocols, including the identity of the compounds represented by formulas III and IV and the mass spectrum in Figure 14.

What does U.S. Patent 9,872,906 protect?

The patent protects solid pharmaceutical compositions containing:

Required element	Claims
Ceftolozane sulfate	1-20
Tazobactam sodium	1-20
Ceftolozane active:tazobactam active ratio of 2:1 by weight	1-10, 12-20
Less than 0.15% impurity relative to ceftolozane sulfate	1-20
Formula III impurity limit after one month at 25°C/60% RH	1-3
Formula IV impurity limit after three months at 25°C/60% RH	9-11, 19-20
Impurity identified by mass spectrum in Figure 14	12-20
Unit dosage form	7
Injectable composition after dissolution in a pharmaceutically acceptable vehicle	8, 11, 18, 20
1,000 mg/500 mg active dose	4, 15
2,000 mg/1,000 mg active dose	5, 16
1,147 mg ceftolozane sulfate and 537 mg tazobactam sodium	6, 17

The patent is therefore a product-quality patent. It does not principally claim:

The ceftolozane molecule;
The tazobactam molecule;
The broad antibacterial combination;
A treatment method for a specific infection;
A manufacturing process for making ceftolozane;
A particular vial, diluent, container, or administration schedule.

The claims instead define a composition by its ingredients, dosage ratio, impurity profile, and stability performance.

How do the independent claims differ?

Claims 1, 9, 12, and 19 are the principal composition claims.

Claim 1

Claim 1 requires a solid composition with ceftolozane sulfate and tazobactam sodium in a 2:1 active ratio. The composition must contain less than 0.15% of formula III relative to ceftolozane sulfate after one month at 25°C and 60% relative humidity.

Claims 2 and 3 narrow the formula III threshold to less than 0.10% and less than 0.03%, respectively.

Claim 9

Claim 9 adds a second impurity limitation. After three months at 25°C and 60% relative humidity, the composition must contain:

Less than 0.15% formula III; and
Less than 1.5% formula IV.

Claim 10 narrows the formula III limit to less than 0.05%.

Claim 12

Claim 12 replaces the structural reference to formula III with an analytical identification based on the mass spectrum depicted in Figure 14. The product must contain less than 0.15% of that compound after one month at 25°C and 60% relative humidity.

Claims 13 and 14 narrow that threshold to less than 0.10% and less than 0.03%.

Claim 19

Claim 19 combines the Figure 14 impurity limitation with the formula IV limitation after three months of storage. It is a combined impurity-control claim and may be more difficult to design around if both impurities arise from common formulation or storage conditions.

What are the key claim-construction issues?

The principal litigation and freedom-to-operate issues concern the meaning and proof of several terms.

“Solid pharmaceutical composition”

The claims require a solid composition before dissolution. A liquid premix may fall outside the literal scope of the solid-composition limitation, although claim 8, 11, 18, and 20 separately cover an injectable composition formed by dissolving the pharmaceutical composition.

A lyophilized vial is the most obvious commercial embodiment. A dry powder, cake, or other solid unit dosage form could also fall within the claims if the remaining limitations are met.

“Comprising”

“Comprising” is an open-ended transition. Additional excipients, stabilizers, buffers, bulking agents, pH modifiers, or processing aids do not ordinarily avoid the claims if the composition still contains the required ceftolozane sulfate, tazobactam sodium, ratio, and impurity profile.

“Provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight”

The ratio is based on active amounts, not necessarily the gross mass of the salts. Claims 4 and 5 correspond to the marketed active doses of 1,000 mg/500 mg and 2,000 mg/1,000 mg.

Claim 6 specifies 1,147 mg ceftolozane sulfate and 537 mg tazobactam sodium. Those salt quantities are not themselves in a 2:1 gross-mass ratio. The claim expressly ties them to the 2:1 ratio of active ceftolozane and active tazobactam.

“Less than”

The thresholds are strict numerical limitations. A measured impurity level of exactly 0.15% would not satisfy a “less than 0.15%” limitation. Analytical method validation, reference standards, peak integration, detection limits, and rounding conventions could become material in an infringement dispute.

HPLC at 254 nm

The claims prescribe HPLC detection at 254 nm. A competitor could not automatically avoid infringement by using another analytical wavelength for development or release testing. The relevant question would be whether the claimed impurity level is met when measured using the method required by the patent or an appropriately equivalent method.

Storage conditions

The claims require testing after:

One month at 25°C and 60% relative humidity; or
Three months at 25°C and 60% relative humidity.

These are product-performance limitations. A product that passes release specifications but exceeds the impurity limit after the claimed storage period could fall outside the relevant claim. Conversely, testing at different temperature or humidity conditions would not directly answer whether the claim is met.

How many patents cover Zerbaxa and ceftolozane-tazobactam?

Zerbaxa is a fixed-dose combination of ceftolozane and tazobactam approved by the FDA in 2014 for specified complicated intra-abdominal and urinary tract infections. The FDA-approved product is supplied as a sterile powder for intravenous infusion and is reconstituted before administration.[1]

The relevant patent estate can be divided into five categories:

Patent category	Subject matter	Relevance to U.S. Patent 9,872,906
Active-ingredient patents	Ceftolozane, tazobactam, or intermediates	Separate from the claimed impurity profile
Combination patents	Ceftolozane plus tazobactam	May overlap in product composition
Formulation patents	Solid, injectable, lyophilized, or stability-controlled products	Closest technical category
Method-of-use patents	Treatment of bacterial infections	Separate infringement theory
Manufacturing patents	Synthesis, salt formation, purification, and impurity control	Potentially important for generic supply

U.S. Patent 9,872,906 is most valuable when combined with formulation, process, and method-of-use patents. Standing alone, it does not cover every ceftolozane-tazobactam product.

What is the Orange Book status of U.S. Patent 9,872,906?

The FDA Orange Book identifies patents submitted by an NDA holder for approved drug products and provides patent-listing and exclusivity information for approved small-molecule medicines.[2] Zerbaxa is an NDA product, not a biologic license application product, so Orange Book listing and Hatch-Waxman certification principles apply.

The commercial significance of U.S. Patent 9,872,906 depends on whether it is listed against the relevant Zerbaxa NDA and whether its listed claims cover the approved product. A patent directed to a solid injectable composition and its impurity profile is the type of patent that can be submitted for Orange Book listing if it claims the approved drug, formulation, or method of use.

An Orange Book listing does not establish validity or infringement. It can, however, trigger a statutory stay of FDA approval when an applicant submits a Paragraph IV certification and the patent owner or NDA holder files an infringement action within the statutory period.[3]

Paragraph IV relevance

A generic applicant seeking approval for ceftolozane-tazobactam could address the patent through:

Paragraph III certification, agreeing not to market until patent expiration;
Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed;
A section viii statement, where only a method-of-use claim is implicated and the applicant omits the protected use; or
A formulation or product design that does not meet the composition limitations.

For this patent, a section viii strategy would generally be less useful if the listed claims are composition claims covering the drug product itself. The applicant would more likely rely on a Paragraph IV challenge or a non-infringing formulation.

When does U.S. Patent 9,872,906 lose exclusivity?

U.S. Patent 9,872,906 issued on January 23, 2018. Its enforceable term is generally calculated from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.[4]

The grant date alone does not establish the expiration date. The controlling date should be taken from the USPTO Patent Center record and the patent’s term information. Any Orange Book entry may show a separate expiration date that incorporates patent-term adjustment or pediatric exclusivity.

FDA regulatory exclusivity is separate from patent exclusivity. Zerbaxa received approval in December 2014. FDA marketing exclusivity for a new chemical entity generally lasts five years, subject to applicable statutory exceptions, while patent rights can continue after regulatory exclusivity ends.[1,5]

What formulation and impurity risks does the patent create?

The patent creates four principal development risks.

1. Lyophilized-product overlap

A generic product that reproduces the Zerbaxa solid powder architecture is more likely to satisfy the “solid pharmaceutical composition” limitation than a materially different presentation.

2. Salt-form constraint

The claims require ceftolozane sulfate and tazobactam sodium. Changing the salt form could avoid literal infringement, but the change would require regulatory, stability, compatibility, and clinical bridging analysis.

3. Impurity-control constraint

A product may contain the same active ingredients and dose ratio but avoid infringement if it exceeds a claimed impurity threshold. That approach carries regulatory risk because impurities above the reference product’s established profile may create a separate FDA quality issue.

4. Analytical proof

The Figure 14 claims may require chemical identification of the relevant impurity through mass spectrometry. A generic applicant would need to compare its impurity peaks with the patent’s disclosed spectrum and evaluate whether the claimed compound is present, rather than relying only on a total related-substances result.

How strong is the patent estate for ceftolozane-tazobactam?

U.S. Patent 9,872,906 has moderate-to-strong product-specific protection but limited broad-molecule coverage.

Strength factor	Assessment
Product specificity	Strong
Coverage of the active ingredients generally	Weak
Coverage of the marketed 2:1 ratio	Strong
Coverage of lyophilized or solid injectable products	Strong if the product meets impurity limits
Ease of designing around by changing excipients	Limited, because excipient changes may not alter the claim elements
Ease of designing around by changing salt form	Potentially meaningful, subject to regulatory constraints
Dependence on analytical testing	High
Exposure to invalidity attacks	Centered on written description, enablement, definiteness, and obviousness
Manufacturing relevance	Indirect, unless a process is required to achieve the claimed impurity profile

The patent’s enforceability may turn on whether the specification adequately supports the numerical impurity thresholds and the Figure 14 compound across the full scope of the claims. The patent owner would also need reliable, reproducible testing to establish infringement.

Which companies are challenging or competing with Zerbaxa?

The principal competitive threat is generic ceftolozane-tazobactam rather than a biosimilar. Ceftolozane-tazobactam is a chemically synthesized small-molecule combination, so the relevant FDA pathway is an abbreviated new drug application, not a biosimilar application under section 351(k) of the Public Health Service Act.[6]

Potential competitors include:

Generic injectable antibiotic manufacturers;
Contract manufacturers supplying sterile beta-lactam products;
Developers of alternative beta-lactam/beta-lactamase inhibitor combinations;
Products competing for hospital treatment of resistant Gram-negative infections.

Direct therapeutic competitors include ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol. These products do not need to overcome the Zerbaxa patent estate, but they compete for similar hospital formulary, infectious-disease, and antimicrobial-stewardship budgets.

What litigation and settlement risks matter?

A Paragraph IV filing could produce litigation under the Hatch-Waxman framework. The key issues would likely include:

Whether the proposed generic is a “solid pharmaceutical composition” before reconstitution;
Whether the product contains ceftolozane sulfate and tazobactam sodium;
Whether active ingredients are present at a 2:1 ratio;
Whether formula III or the Figure 14 impurity is present below the claimed threshold;
Whether formula IV remains below 1.5% after three months;
Whether the testing protocol is reproducible and legally sufficient;
Whether the patent claims are enabled and definite; and
Whether earlier formulations or stability data render the claims obvious.

A settlement could include a licensed entry date, authorized-generic arrangements, manufacturing restrictions, or an agreement not to challenge other patents. A settlement date cannot be inferred from the patent claims and should not be treated as evidence of patent strength.

What is the revenue exposure from this patent?

Merck acquired Cubist Pharmaceuticals in 2015, bringing Zerbaxa into Merck’s portfolio.[7] Merck’s public reporting generally presents Zerbaxa within broader hospital and acute-care product reporting rather than consistently disclosing a standalone global revenue figure. The commercial exposure is therefore tied to the product’s hospital use, antimicrobial-resistance demand, and the timing of generic injectable entry.

The patent is most commercially important during the period in which:

Zerbaxa remains a meaningful hospital product;
No approved generic has established substitutable supply;
The formulation is difficult to reproduce at scale;
Competing beta-lactam/beta-lactamase inhibitor products do not fully replace demand.

A generic that avoids the patent but requires a different salt, impurity profile, or dosage presentation may face additional FDA comparability and manufacturing costs.

What geographic coverage does the patent provide?

U.S. Patent 9,872,906 provides rights only in the United States. It does not directly protect sales, manufacturing, importation, or formulation activity in Europe, Japan, China, or other jurisdictions.

The corresponding international landscape must be assessed separately through:

PCT applications;
National-phase applications;
Granted European patents;
Country-specific validation;
Patent-term adjustments or supplementary protection certificates;
Local Orange Book equivalents or regulatory patent-linkage systems.

U.S. infringement can still arise from importing a covered product manufactured abroad or offering it for U.S. commercial distribution, subject to the applicable statutory provisions.

Key Takeaways

U.S. Patent 9,872,906 is a formulation and impurity-profile patent for ceftolozane-tazobactam.
The core limitations are ceftolozane sulfate, tazobactam sodium, a 2:1 active ratio, and specified impurity thresholds after controlled storage.
Claims 4-6 and 15-17 map closely to the 1,000 mg/500 mg, 2,000 mg/1,000 mg, and 1,147 mg/537 mg presentations.
Claims 8, 11, 18, and 20 extend protection to injectable compositions made by dissolving the claimed solid composition.
The patent does not broadly claim ceftolozane, tazobactam, or the antibacterial combination independent of formulation and impurity performance.
Generic risk is highest for a lyophilized product using the same salts and 2:1 active ratio.
The main design-around options involve salt selection, solid-state architecture, impurity generation, and formulation process, but each creates separate regulatory and manufacturing risks.
Ceftolozane-tazobactam is a small-molecule product. Biosimilar analysis is not applicable; ANDA and Paragraph IV analysis is the relevant framework.
The precise expiration and Orange Book status must be determined from current USPTO and FDA records, including any patent-term adjustment, terminal disclaimer, listing status, and pediatric extension.

FAQs About U.S. Patent 9,872,906

Does U.S. Patent 9,872,906 cover Zerbaxa by brand name?

No. It covers compositions meeting the stated ingredient, ratio, impurity, stability, and dosage limitations. Zerbaxa is a likely commercial embodiment, but the claims do not depend on the brand name.

Can a generic use the same 1,000 mg/500 mg dose and avoid the patent?

Possibly, but not automatically. The generic would need to avoid at least one required limitation, such as the specified salt forms or impurity thresholds, while remaining pharmaceutically acceptable and approvable by FDA.

Are the impurity limits release specifications?

Not necessarily. The claims define composition performance after specified storage periods. A release specification and a patent infringement test are separate analytical and legal questions.

Does changing the excipients avoid infringement?

Usually not by itself. The claims use “comprising,” so additional or different excipients may remain within scope if all claimed ingredients, ratios, and impurity limits are present.

Is a ceftolozane-tazobactam biosimilar possible?

The product is regulated as a small-molecule drug combination. A competing product would generally pursue an ANDA or, depending on its formulation and clinical differences, a full NDA pathway rather than a biosimilar application.

References

U.S. Food and Drug Administration. (2014). FDA approves new antibacterial drug Zerbaxa to treat certain complicated infections. https://www.fda.gov
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
21 U.S.C. § 355(j). Abbreviated applications for new drugs. https://uscode.house.gov
United States Patent and Trademark Office. (n.d.). Patent term adjustment. https://www.uspto.gov/patents/laws/patent-term-adjustment
21 U.S.C. § 355. Applications for FDA approval to market a new drug. https://uscode.house.gov
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application ANDA process. https://www.fda.gov/drugs
Merck & Co., Inc. (2015). Merck completes acquisition of Cubist Pharmaceuticals. https://www.merck.com/news/

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014227660	⤷ Start Trial
Australia	2015200599	⤷ Start Trial
Brazil	112015023523	⤷ Start Trial
Canada	2906151	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 9,872,906